Vigil Neuroscience Update on its Small Molecule Alzheimer's Program

 Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease -

- IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial clinical hold related to maximum exposure limit –

- Phase 1 dosing expected to commence in October 2023; No anticipated delays in current clinical development plans -

- Company to host virtual R&D event highlighting its small molecule TREM2 agonist program on September 13, 2023 -

To access the live webcast of this event, please register here or visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com. An archived replay will be available for approximately 90 days following the presentation.

https://finance.yahoo.com/news/vigil-neuroscience-announces-small-molecule-200500454.html